Daraxonrasib
Drug timelines are a Plus or Pro feature.
9 regulatory and trial events tracked for Daraxonrasib, covering 2025-12-12 to 2026-06-02. Get the full timeline:
Most recent: Clinical Trial Update: Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) [Phase 3]